Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment
Vinson & Elkins served as co-counsel to Reata Pharmaceuticals, Inc. in connection with a $350 million royalty and equity investment in Reata led by funds managed by Blackstone Life Sciences to fund the development and potential commercialization of bardoxolone methyl, an investigational once-daily oral therapy being studied for chronic kidney disease in Alport syndrome, autosomal dominant polycystic kidney disease and other associated potential future indications.
The financing also includes a $50 million investment in 340,793 shares of Reata’s Class A common stock at $146.72 per share. Reata will receive the $350 million investment at closing, which is expected to occur on or before June 24, 2020.
The V&E team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associate Breanna Kelly.
For more information, please speak with our media contacts.
Key Contacts
Related Insights
- InsightInsight
V&E SEC Update
September 3, 2020 - Event RecapEvent RecapThursday, August 13, 2020Video